237 related articles for article (PubMed ID: 24662671)
1. Concurrent rho-kinase and tyrosine kinase platelet-derived growth factor inhibition in experimental pulmonary hypertension.
Jasińska-Stroschein M; Owczarek J; Plichta P; Orszulak-Michalak D
Pharmacology; 2014; 93(3-4):145-50. PubMed ID: 24662671
[TBL] [Abstract][Full Text] [Related]
2. The beneficial impact of fasudil and sildenafil on monocrotaline-induced pulmonary hypertension in rats: a hemodynamic and biochemical study.
Jasińska-Stroschein M; Owczarek J; Łuczak A; Orszulak-Michalak D
Pharmacology; 2013; 91(3-4):178-84. PubMed ID: 23428587
[TBL] [Abstract][Full Text] [Related]
3. Role of Src tyrosine kinases in experimental pulmonary hypertension.
Pullamsetti SS; Berghausen EM; Dabral S; Tretyn A; Butrous E; Savai R; Butrous G; Dahal BK; Brandes RP; Ghofrani HA; Weissmann N; Grimminger F; Seeger W; Rosenkranz S; Schermuly RT
Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1354-65. PubMed ID: 22516066
[TBL] [Abstract][Full Text] [Related]
4. Imatinib attenuates monocrotaline pulmonary hypertension and has potent vasodilator activity in pulmonary and systemic vascular beds in the rat.
Pankey EA; Thammasiboon S; Lasker GF; Baber S; Lasky JA; Kadowitz PJ
Am J Physiol Heart Circ Physiol; 2013 Nov; 305(9):H1288-96. PubMed ID: 23997103
[TBL] [Abstract][Full Text] [Related]
5. Treatment with platelet-derived growth factor (PDGF) and rock inhibitors is related to declined nerve growth factor (NGF) signaling in an experimental model of rat pulmonary hypertension.
Jasińska-Stroschein M; Oszajca K; Świtlik W; Ruchwa J; Orszulak-Michalak D
Pharmacol Rep; 2017 Jun; 69(3):532-535. PubMed ID: 28363184
[TBL] [Abstract][Full Text] [Related]
6. Delivery of imatinib-incorporated nanoparticles into lungs suppresses the development of monocrotaline-induced pulmonary arterial hypertension.
Akagi S; Nakamura K; Miura D; Saito Y; Matsubara H; Ogawa A; Matoba T; Egashira K; Ito H
Int Heart J; 2015 May; 56(3):354-9. PubMed ID: 25902888
[TBL] [Abstract][Full Text] [Related]
7. Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil.
Mouchaers KT; Schalij I; de Boer MA; Postmus PE; van Hinsbergh VW; van Nieuw Amerongen GP; Vonk Noordegraaf A; van der Laarse WJ
Eur Respir J; 2010 Oct; 36(4):800-7. PubMed ID: 20351034
[TBL] [Abstract][Full Text] [Related]
8. Effects of combined therapy with a Rho-kinase inhibitor and prostacyclin on monocrotaline-induced pulmonary hypertension in rats.
Tawara S; Fukumoto Y; Shimokawa H
J Cardiovasc Pharmacol; 2007 Aug; 50(2):195-200. PubMed ID: 17703136
[TBL] [Abstract][Full Text] [Related]
9. Reversal effects of low-dose imatinib compared with sunitinib on monocrotaline-induced pulmonary and right ventricular remodeling in rats.
Leong ZP; Okida A; Higuchi M; Yamano Y; Hikasa Y
Vascul Pharmacol; 2018 Jan; 100():41-50. PubMed ID: 29100963
[TBL] [Abstract][Full Text] [Related]
10. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling.
Klein M; Schermuly RT; Ellinghaus P; Milting H; Riedl B; Nikolova S; Pullamsetti SS; Weissmann N; Dony E; Savai R; Ghofrani HA; Grimminger F; Busch AE; Schäfer S
Circulation; 2008 Nov; 118(20):2081-90. PubMed ID: 18955668
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of rho kinase attenuates high flow induced pulmonary hypertension in rats.
Li FH; Xia W; Li AW; Zhao CF; Sun RP
Chin Med J (Engl); 2007 Jan; 120(1):22-9. PubMed ID: 17254483
[TBL] [Abstract][Full Text] [Related]
12. HMG-COA reductase inhibitors: An opportunity for the improvement of imatinib safety. An experimental study in rat pulmonary hypertension.
Jasińska-Stroschein M; Owczarek J; Surowiecka A; Kącikowska J; Orszulak-Michalak D
Pharmacol Rep; 2015 Feb; 67(1):32-7. PubMed ID: 25560572
[TBL] [Abstract][Full Text] [Related]
13. Cocktail of Superoxide Dismutase and Fasudil Encapsulated in Targeted Liposomes Slows PAH Progression at a Reduced Dosing Frequency.
Gupta N; Rashid J; Nozik-Grayck E; McMurtry IF; Stenmark KR; Ahsan F
Mol Pharm; 2017 Mar; 14(3):830-841. PubMed ID: 28165252
[TBL] [Abstract][Full Text] [Related]
14. Effects of rho-kinase inhibition on pulmonary hypertension, lung growth, and structure in neonatal rats chronically exposed to hypoxia.
Ziino AJ; Ivanovska J; Belcastro R; Kantores C; Xu EZ; Lau M; McNamara PJ; Tanswell AK; Jankov RP
Pediatr Res; 2010 Feb; 67(2):177-82. PubMed ID: 19858775
[TBL] [Abstract][Full Text] [Related]
15. Rho kinase mediates right ventricular systolic dysfunction in rats with chronic neonatal pulmonary hypertension.
Gosal K; Dunlop K; Dhaliwal R; Ivanovska J; Kantores C; Desjardins JF; Connelly KA; McNamara PJ; Jain A; Jankov RP
Am J Respir Cell Mol Biol; 2015 Jun; 52(6):717-27. PubMed ID: 25337652
[TBL] [Abstract][Full Text] [Related]
16. Attenuation of pulmonary hypertension secondary to left ventricular dysfunction in the rat by Rho-kinase inhibitor fasudil.
Dai ZK; Wu BN; Chen IC; Chai CY; Wu JR; Chou SH; Yeh JL; Chen IJ; Tan MS
Pediatr Pulmonol; 2011 Jan; 46(1):45-59. PubMed ID: 20717937
[TBL] [Abstract][Full Text] [Related]
17. Reversal of experimental pulmonary hypertension by PDGF inhibition.
Schermuly RT; Dony E; Ghofrani HA; Pullamsetti S; Savai R; Roth M; Sydykov A; Lai YJ; Weissmann N; Seeger W; Grimminger F
J Clin Invest; 2005 Oct; 115(10):2811-21. PubMed ID: 16200212
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with fasudil and sildenafil ameliorates monocrotaline-induced pulmonary hypertension and survival in rats.
Elias-Al-Mamun M; Satoh K; Tanaka S; Shimizu T; Nergui S; Miyata S; Fukumoto Y; Shimokawa H
Circ J; 2014; 78(4):967-76. PubMed ID: 24553194
[TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension.
Hatano M; Yao A; Shiga T; Kinugawa K; Hirata Y; Nagai R
Int Heart J; 2010 Jul; 51(4):272-6. PubMed ID: 20716845
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension.
Chhina MK; Nargues W; Grant GM; Nathan SD
Future Cardiol; 2010 Jan; 6(1):19-35. PubMed ID: 20014985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
